Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.56 |
| ▸ | EGFR | P00533 | 8/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | YES1 | P07947 | 2/20 | 0.54 |
| ▸ | CSK | P41240 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGR | P09769 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276447 | 0.86 | SRC (0.69) | SRCEGFRKDRLCKYES1 | |
| SCHEMBL13879173 | 0.82 | EGFR (0.43) | SRCEGFRKDR | |
| SCHEMBL13879171 | 0.82 | SRC (0.84) | SRCEGFRKDRLCKYES1 | |
| Hydrochloric Acid SCHEMBL3280216 | 0.76 | SRC (0.63) | SRCEGFRKDRLCKYES1 | |
| SCHEMBL18533998 | 0.76 | SRC (0.69) | SRCEGFRKDRLCKYES1 | |
| SCHEMBL3275753 | 0.76 | SRC (0.69) | SRCEGFRKDRLCKYES1 | |
| SCHEMBL3280225 | 0.74 | EGFR (0.48) | SRCEGFRKDR | |
| SCHEMBL18533999 | 0.73 | SRC (0.79) | SRCEGFRKDRLCKYES1 | |
| SCHEMBL17934359 | 0.73 | EGFR (0.86) | EGFR | |
| SCHEMBL3279071 | 0.72 | SRC (0.80) | SRCEGFRKDRLCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | SRC 529/4885EGFR 2358/4885KDR 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.